These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
766 related articles for article (PubMed ID: 32406563)
1. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance. Zhao S; Ma D; Xiao Y; Li XM; Ma JL; Zhang H; Xu XL; Lv H; Jiang WH; Yang WT; Jiang YZ; Zhang QY; Shao ZM Oncologist; 2020 Oct; 25(10):e1481-e1491. PubMed ID: 32406563 [TBL] [Abstract][Full Text] [Related]
2. Subtyping of triple-negative breast cancers: its prognostication and implications in diagnosis of breast origin. Hu H; Tong K; Tsang JY; Ko CW; Tam F; Loong TC; Tse GM ESMO Open; 2024 Apr; 9(4):102993. PubMed ID: 38613910 [TBL] [Abstract][Full Text] [Related]
3. Immunohistochemistry-based molecular subtyping of triple-negative breast cancer and its prognostic significance. Leeha M; Kanokwiroon K; Laohawiriyakamol S; Thongsuksai P Pathol Oncol Res; 2023; 29():1611162. PubMed ID: 37274773 [No Abstract] [Full Text] [Related]
4. Feasibility of Classification of Triple Negative Breast Cancer by Immunohistochemical Surrogate Markers. Kim S; Moon BI; Lim W; Park S; Cho MS; Sung SH Clin Breast Cancer; 2018 Oct; 18(5):e1123-e1132. PubMed ID: 29754847 [TBL] [Abstract][Full Text] [Related]
5. Genomic characterization reveals distinct mutational landscapes and therapeutic implications between different molecular subtypes of triple-negative breast cancer. Li RQ; Yan L; Zhang L; Ma HX; Wang HW; Bu P; Xi YF; Lian J Sci Rep; 2024 May; 14(1):12386. PubMed ID: 38811720 [TBL] [Abstract][Full Text] [Related]
6. High expression of TLR3 in triple-negative breast cancer predicts better prognosis-data from the Fudan University Shanghai Cancer Center cohort and tissue microarrays. Fan L; Sui XY; Jin X; Zhang WJ; Zhou P; Shao ZM BMC Cancer; 2023 Apr; 23(1):298. PubMed ID: 37005579 [TBL] [Abstract][Full Text] [Related]
7. Subclassifying triple-negative breast cancers and its potential clinical utility. Lian J; Ma HX; Xu EW; Bu P; Yun KM; Xi YF Virchows Arch; 2022 Jul; 481(1):13-21. PubMed ID: 35471664 [TBL] [Abstract][Full Text] [Related]
8. Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer. Liu YR; Jiang YZ; Xu XE; Yu KD; Jin X; Hu X; Zuo WJ; Hao S; Wu J; Liu GY; Di GH; Li DQ; He XH; Hu WG; Shao ZM Breast Cancer Res; 2016 Mar; 18(1):33. PubMed ID: 26975198 [TBL] [Abstract][Full Text] [Related]
9. Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial. Fan L; Wang ZH; Ma LX; Wu SY; Wu J; Yu KD; Sui XY; Xu Y; Liu XY; Chen L; Zhang WJ; Jin X; Xiao Q; Shui RH; Xiao Y; Wang H; Yang YS; Huang XY; Cao AY; Li JJ; Di GH; Liu GY; Yang WT; Hu X; Xia Y; Liang QN; Jiang YZ; Shao ZM Lancet Oncol; 2024 Feb; 25(2):184-197. PubMed ID: 38211606 [TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical Profile of Triple-Negative Breast Cancers: SOX10 and AR Dual Negative Tumors Have Worse Outcomes. Rammal R; Goel K; Motanagh SA; Carter GJ; Clark BZ; Fine JL; Harinath L; Villatoro TM; Yu J; Bhargava R Mod Pathol; 2024 Jul; 37(7):100517. PubMed ID: 38763422 [TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer. Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308 [TBL] [Abstract][Full Text] [Related]
12. A triple-negative breast cancer surrogate subtype classification that correlates with gene expression subtypes. Yoo TK; Kang J; Lee A; Chae BJ Breast Cancer Res Treat; 2022 Feb; 191(3):599-610. PubMed ID: 35018542 [TBL] [Abstract][Full Text] [Related]
13. Triple-Negative Breast Cancer Subclassified by Immunohistochemistry: Correlation with Clinical and Pathological Outcomes in Patients Receiving Neoadjuvant Chemotherapy. Paula B; Crocamo S; de Sousa CAM; Valverde P; Rezende F; Abdelhay E Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892013 [TBL] [Abstract][Full Text] [Related]
14. Molecular Subtyping of Triple Negative Breast Cancer by Surrogate Immunohistochemistry Markers. Kumar S; Bal A; Das A; Bhattacharyya S; Laroiya I; Khare S; Singh G Appl Immunohistochem Mol Morphol; 2021 Apr; 29(4):251-257. PubMed ID: 33337632 [TBL] [Abstract][Full Text] [Related]
15. Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6/STAT3 signaling. Liu H; Yan R; Xiao Z; Huang X; Yao J; Liu J; An G; Ge Y Breast Cancer Res; 2023 Apr; 25(1):43. PubMed ID: 37069669 [TBL] [Abstract][Full Text] [Related]
16. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts. Coussy F; Lavigne M; de Koning L; Botty RE; Nemati F; Naguez A; Bataillon G; Ouine B; Dahmani A; Montaudon E; Painsec P; Chateau-Joubert S; Laetitia F; Larcher T; Vacher S; Chemlali W; Briaux A; Melaabi S; Salomon AV; Guinebretiere JM; Bieche I; Marangoni E Theranostics; 2020; 10(4):1531-1543. PubMed ID: 32042320 [TBL] [Abstract][Full Text] [Related]
17. Imaging features of triple-negative breast cancers according to androgen receptor status. Candelaria RP; Adrada BE; Wei W; Thompson AM; Santiago L; Lane DL; Huang ML; Arribas EM; Rauch GM; Symmans WF; Gilcrease MZ; Huo L; Lim B; Ueno NT; Moulder SL; Yang WT Eur J Radiol; 2019 May; 114():167-174. PubMed ID: 31005169 [TBL] [Abstract][Full Text] [Related]
18. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Burstein MD; Tsimelzon A; Poage GM; Covington KR; Contreras A; Fuqua SA; Savage MI; Osborne CK; Hilsenbeck SG; Chang JC; Mills GB; Lau CC; Brown PH Clin Cancer Res; 2015 Apr; 21(7):1688-98. PubMed ID: 25208879 [TBL] [Abstract][Full Text] [Related]
19. Comparison of the Clinicopathologic Features and T-Cell Infiltration of B7-H3 and B7-H4 Expression in Triple-negative Breast Cancer Subtypes. Kim NI; Park MH; Cho N; Lee JS Appl Immunohistochem Mol Morphol; 2022 Apr; 30(4):246-256. PubMed ID: 35384874 [TBL] [Abstract][Full Text] [Related]
20. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer. Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]